Since p53 in retinoblastoma is typically wild-type and the G1-S checkpoint regulator Rb is altered, we envisaged targeting pyrimidine ribonucleotide synthesis through DHODH inhibition as a viable option to accumulate cells in S phase and induce a cell death response. The gene discussed is TP53; the disease is retinoblastoma.